Details of Disease

General Information of Disease (ID: DISWKMCK)

• Disease Name: Hepatitis virus infection
• Disease Class: 1E50-1E51: Hepatitis virus infection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISWKMCK: Hepatitis virus infection
• ICD Code:
  ICD-11: ICD-11: 1E50-1E51
  ICD-9: ICD-9: 573.3
  Expand ICD-9: 573.3

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Emetine	DMCT2YF	Approved	Small molecular drug	[1]
Emtricitabine	DMBMUWZ	Approved	Small molecular drug	[2]
Havrix	DMP2KQ5	Approved	NA	[1]
Merimepodib	DM0HS92	Approved	Small molecular drug	[3]
Thymalfasin	DMADCYE	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MF-101	DM8Z0I3	Phase 3	NA	[4]
BILN-2061	DM2J36F	Phase 2	Small molecular drug	[5]
HepeX-B	DMROGL6	Phase 2	NA	[6]
Hi8 HBV vaccine	DMCEQXC	Phase 2	NA	[7]
IC-41	DMX3T41	Phase 2	NA	[8]
JKB-122	DMARQ0H	Phase 2	NA	[9]
Pradefovir	DM1O0DV	Phase 2	Small molecular drug	[10]
VLI-03A	DMT5NA7	Phase 2	NA	[11]
CRX-675	DMHDSYF	Phase 1	NA	[12]
Drug 2878175	DMNFEC6	Phase 1	NA	[13]
HCV vaccine	DMMLMC1	Phase 1	NA	[14]
PdpSC18	DMR2BBK	Phase 1	NA	[15]
Tarvacin Anti-Viral	DMGUXE8	Phase 1	NA	[16]

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IFN-alpha 2B-XL	DMBDT0A	Discontinued in Phase 2	NA	[17]
ME-3738	DMDXTQM	Discontinued in Phase 2	NA	[18]
PEG-Infergen	DMGD20T	Discontinued in Phase 2	NA	[19]
Valtorcitabine	DMXQCBU	Discontinued in Phase 2	Small molecular drug	[20]
AVI-4065	DMGEDAY	Discontinued in Phase 1/2	Antisense drug	[21]
ANA971	DM2UR2E	Discontinued in Phase 1	NA	[22]
EHC18	DMV9BLA	Discontinued in Phase 1	NA	[23]
HCV-086	DM2RF06	Discontinued in Phase 1	Small molecular drug	[24]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
C-0334578	DMZJ8D4	Investigative	NA	[25]
CNJ-H01	DMM24FN	Investigative	NA	[25]
Creaferon	DMSLCJ9	Investigative	NA	[25]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008158)
• [4] ClinicalTrials.gov (NCT00906308) A Study of MF101 in Postmenopausal Women. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02226939) Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00228592) HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00259844) Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT00601770) Virological Response Study of the HCV Vaccine IC41. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT02556372) Liver Test Study of Using JKB-122 in AIH Patients.
• [10] ClinicalTrials.gov (NCT00230503) Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Hep C Ltd.
• [12] ClinicalTrials.gov (NCT00076037) Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT02014571) Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT00445419) Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides. U.S. National Institutes of Health.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009216)
• [16] Clinical pipeline report, company report or official report of Peregrine Pharmaceuticals.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020211)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020547)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017958)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013710)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023108)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020329)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018235)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020428)
• [25] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [26] Clinical pipeline report, company report or official report of SciClone Pharmaceuticals.